公开(公告)号：US11858990B2

公开(公告)日：2024-01-02

申请号：US16804018

申请日：2020-02-28

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Simon Kollnberger ,  Benjamin Rossi ,  Hélène Sicard ,  Carine Paturel ,  Stéphanie Cornen ,  Stéphanie Zerbib

IPC: A61P35/00 ,  C07K16/28 ,  G01N33/569 ,  A61K39/00

CPC classification number: C07K16/2803 ,  G01N33/56966 ,  G01N33/56972 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  G01N2333/70503 ,  G01N2800/24 ,  G01N2800/52 ,  G01N2800/7095

Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

公开(公告)号：US11845795B2

公开(公告)日：2023-12-19

申请号：US16677709

申请日：2019-11-08

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  C07K16/2866 ,  C07K2317/31 ,  C07K2317/71 ,  C07K2317/92 ,  C07K2319/30

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US11578136B2

公开(公告)日：2023-02-14

申请号：US16477506

申请日：2018-03-16

Applicant: INNATE PHARMA ,  OREGA BIOTECH

Inventor： Stéphanie Chanteux ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US20230025732A1

公开(公告)日：2023-01-26

申请号：US17855510

申请日：2022-06-30

Applicant: Innate Pharma ,  Orega Biotech

Inventor： Stéphanie Chanteux ,  Laurent Gauthier ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US10519234B2

公开(公告)日：2019-12-31

申请号：US15321650

申请日：2015-06-23

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: C07K16/28

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US20160369002A1

公开(公告)日：2016-12-22

申请号：US15190337

申请日：2016-06-23

Applicant: INNATE PHARMA

Inventor： Laurent GAUTHIER ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: C07K16/28

CPC classification number: C07K16/2896 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/283 ,  C07K16/2866 ,  C07K16/2887 ,  C07K2317/31 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2319/30 ,  A61K39/001102 ,  A61K39/001104

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

Abstract translation: 在不存在靶细胞的情况下，提供结合并特异性地重定向NK细胞以裂解感兴趣的靶细胞的多特异性蛋白质而没有NK细胞的非特异性激活。 这些蛋白质可用于治疗疾病，特别是癌症或感染性疾病。

公开(公告)号：US20230340143A1

公开(公告)日：2023-10-26

申请号：US18168522

申请日：2023-02-13

Applicant: Innate Pharma ,  OREGA BIOTECH

Inventor： Stéphanie Chanteux ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  G01N33/574 ,  A61P35/00

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  G01N33/57492 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US11623954B2

公开(公告)日：2023-04-11

申请号：US16629588

申请日：2018-07-09

Applicant: INNATE PHARMA

Inventor： Stéphanie Cornen ,  Benjamin Rossi ,  Nicolai Wagtmann ,  Laurent Gauthier

IPC: C07K16/28 ,  A61K39/00

Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.

公开(公告)号：US11083785B2

公开(公告)日：2021-08-10

申请号：US15776452

申请日：2016-11-17

Applicant: INNATE PHARMA

Inventor： Stephanie Cornen ,  Laurent Gauthier ,  Benjamin Rossi ,  Nicolai Wagtmann

IPC: C07K14/705 ,  A61K39/00 ,  C07K16/28 ,  A61P35/00

Abstract: This disclosure relates to agents that bind and neutralize the inhibitory activity of Siglec-10 in lymphocytes, notably by inhibiting the binding of Siglec-10 to its sialic acid ligands on target cells, notably tumor cells. Such agents can be used for the treatment of cancers.

公开(公告)号：US11001629B2

公开(公告)日：2021-05-11

申请号：US16066688

申请日：2016-12-20

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: C07K16/28 ,  C07K16/46

Abstract: NKp-46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.